Company / Cash & Equivalents
ANI Pharmaceuticals, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$285.6M
FY2025
5-year range
$48.2M / $285.6M
FY2021-FY2025
Trend
+97.1%
vs FY2024
Sector context
#66 of 207
Health Care
What the data says
At $286M, ANI Pharmaceuticals, Inc.'s cash & equivalents ranks #66 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $8M in FY2020 to $286M in FY2025.
Based on SEC 10-K filings.
$286M in FY2025 with a 5-year CAGR of +105.1%.
Improved from $221M to $286M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +80.9%
- 5-Year CAGR
- +105.1%
- 10-Year CAGR
- -
Sector benchmark
#66 of 207 in Health CareTop 32% of 207This company $285.6M Sector average $669.5M
▼
-57.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +105.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 97.1% year-over-year.
- Ranks #66 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $285.6M | +97.1% |
| FY2024 | $144.9M | -34.5% |
| FY2023 | $221.1M | +358.5% |
| FY2022 | $48.2M | -51.9% |
| FY2021 | $100.3M | +1175.4% |
| FY2020 | $7.9M | -87.4% |
| FY2019 | $62.3M | +44.9% |
| FY2018 | $43.0M | +38.1% |
| FY2017 | $31.1M | +13.8% |
| FY2016 | $27.4M | +146.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026